Search

Your search keyword '"Tu, Shi‐Ming"' showing total 25 results
Start Over Author "Tu, Shi‐Ming" Publisher wiley
25 results on '"Tu, Shi‐Ming"'

1. Predictive capacity of a miRNA panel in identifying teratoma in post‐chemotherapy consolidation surgeries

Author

Moore, Joseph A., primary, Lehner, Michael J., additional, Anfossi, Simone, additional, Datar, Saumil, additional, Tidwell, Rebecca S., additional, Campbell, Matthew, additional, Shah, Amishi Y., additional, Ward, John F., additional, Karam, Jose A., additional, Wood, Christopher G., additional, Pisters, Lois L., additional, Calin, George A., additional, and Tu, Shi‐Ming, additional

Published
2022
Full Text
View/download PDF

2. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications

Author

Umbreit, Eric C., primary, McIntosh, Andrew G., additional, Suk‐ouichai, Chalairat, additional, Segarra, Luis A., additional, Holland, Levi C., additional, Fellman, Bryan M., additional, Williams, Stephen B., additional, Thomas, Arun Z., additional, Tu, Shi‐Ming, additional, Pettaway, Curtis A., additional, Pisters, Louis L., additional, Ward, John F., additional, Wood, Christopher G., additional, and Karam, Jose A., additional

Published
2020
Full Text
View/download PDF

3. Patterns of metastases of prostatic ductal adenocarcinoma

Author

Ranasinghe, Weranja K. B., primary, Brooks, Nathan A., additional, Elsheshtawi, Mohamed A., additional, Davis, John W., additional, Bathala, Tharakeswara K., additional, Tang, Chad, additional, Troncoso, Patricia, additional, Aparicio, Ana, additional, Tu, Shi‐Ming, additional, Pisters, Louis L., additional, and Chapin, Brian F., additional

Published
2020
Full Text
View/download PDF

5. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer

Author

Tu, Shi‐Ming, primary, Bilen, Mehmet Asim, additional, Hess, Kenneth R., additional, Broaddus, Russell R., additional, Kopetz, Scott, additional, Wei, Chongjuan, additional, Pagliaro, Lance C., additional, Karam, Jose A., additional, Ward, John F., additional, Wood, Christopher G., additional, Rao, Priya, additional, Tu, Zachary H., additional, General, Rosale, additional, Chen, Adrienne H., additional, Nieto, Yago L., additional, Yeung, Sai‐ching J., additional, Lin, Sue‐Hwa, additional, Logothetis, Christopher J., additional, and Pisters, Louis L., additional

Published
2016
Full Text
View/download PDF

6. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

Author

Bilen, Mehmet Asim, primary, Johnson, Marcella M., additional, Mathew, Paul, additional, Pagliaro, Lance C., additional, Araujo, John C., additional, Aparicio, Ana, additional, Corn, Paul G., additional, Tannir, Nizar M., additional, Wong, Franklin C., additional, Fisch, Michael J., additional, Logothetis, Christopher J., additional, and Tu, Shi-Ming, additional

Published
2014
Full Text
View/download PDF

8. Ductal adenocarcinoma of the prostate

Author

Tu, Shi-Ming, primary, Lopez, Adriana, additional, Leibovici, Dan, additional, Bilen, Mehmet A., additional, Evliyaoglu, Ferhat, additional, Aparicio, Ana, additional, Guo, Charles C., additional, Kuban, Deborah A., additional, Johnson, Marcy M., additional, and Pisters, Louis L., additional

Published
2009
Full Text
View/download PDF

20. Prostate carcinoma with testicular or penile metastases

Author

Tu, Shi-Ming, primary, Reyes, Adriana, additional, Maa, April, additional, Bhowmick, Deb, additional, Pisters, Louis L., additional, Pettaway, Curtis A., additional, Lin, Sue-Hwa, additional, Troncoso, Patricia, additional, and Logothetis, Christopher J., additional

Published
2002
Full Text
View/download PDF

24. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Author

Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, and Tu SM

Subjects
Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms secondary, Combined Modality Therapy methods, Diphosphonates administration & dosage, Diphosphonates therapeutic use, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Humans, Imidazoles administration & dosage, Imidazoles therapeutic use, Male, Prostatic Neoplasms pathology, Strontium Radioisotopes therapeutic use, Survival Analysis, Treatment Outcome, Zoledronic Acid, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bone Neoplasms therapy, Prostatic Neoplasms therapy, Strontium Radioisotopes administration & dosage
Abstract

Background: Radiopharmaceutical use may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides a clinical benefit to patients with advanced castrate-sensitive prostate cancer has not been investigated., Methods: Eighty male patients were enrolled, and 79 were randomized: 40 to the control arm and 39 to the strontium-89 (Sr-89) arm. After randomization, patients in both study arms received ADT, doxorubicin, and zoledronic acid. Kaplan-Meier methodology was used to evaluate the progression-free survival (PFS) time. Multivariate Cox proportional hazards regression was used to evaluate the effects of Sr-89 after controlling for the number of bone metastases., Results: The median follow-up time for the 29 patients alive at the last follow-up was 76.9 months (range, 0.07-103.4 months). The median PFS time was 18.5 months (95% confidence interval, 9.7-49.4 months) for the control arm and 12.9 months (95% confidence interval, 8.9-72.5 months) for the Sr-89 arm (P = .86). No patient developed myelodysplastic syndrome or a hematologic malignancy. An unplanned subgroup analysis suggested increased efficacy of bone-targeted therapy with a greater extent of bone involvement (ie, >6 bone metastases vs ≤6 bone metastases on the bone scan)., Conclusions: The data showed that bone-targeted therapy using 1 dose of Sr-89 combined with chemohormonal ablation therapy did not favorably affect the PFS of patients with castrate-sensitive prostate cancer. The combined therapy was feasible and safe. Whether such bone-targeted therapy provides a favorable outcome for those patients with a greater tumor burden in the bone warrants further investigation., (© 2014 American Cancer Society.)

Published
2015
Full Text
View/download PDF

25. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Author

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, and Tu SM

Subjects
Adult, Aged, Antineoplastic Agents therapeutic use, Biomarkers, Tumor blood, Biomarkers, Tumor urine, Bone Density Conservation Agents therapeutic use, Bone Neoplasms pathology, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pilot Projects, Zoledronic Acid, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Carcinoma, Renal Cell secondary, Diphosphonates therapeutic use, Imidazoles therapeutic use, Interferon-gamma therapeutic use, Kidney Neoplasms secondary, Thalidomide therapeutic use
Abstract

Background: The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases., Methods: Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon-gamma (100 microg) was given subcutaneously once a week. Patients were evaluated for time to skeletal-related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers. RESULTS.: Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1-48 weeks). The median time to a skeletal-related event was 12.0 weeks (range, 3.9-46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels., Conclusions: In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-gamma was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases., (Copyright 2006 American Cancer Society.)

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results